Neuropathological measures of increased tau phosphorylation across the Down syndrome lifespan
-
By
-
March 22, 2026
Objective:
To quantify the neuropathology burdens of pThr181, pThr231, and pThr217 in the frontal cortex of individuals with Down syndrome (DS) and late-onset Alzheimer's disease (LOAD), specifically focusing on individuals aged 1 to 96 years, and to assess changes across the lifespan.
Key Findings:
- Individuals with DS show a significantly more rapid accumulation of p-tau pathology compared to those with LOAD, indicating a critical difference in disease progression.
- By age 40, virtually all individuals with DS exhibit Aβ and p-tau neuropathology, highlighting the urgent need for monitoring.
- There is a differential age-associated increase in p-tau epitopes in DS across the lifespan, suggesting unique pathological trajectories.
Interpretation:
The study highlights the accelerated tau pathology in individuals with Down syndrome compared to typical late-onset Alzheimer's disease, suggesting a critical need for early intervention strategies tailored to this population.
Limitations:
- The study is limited by the availability of postmortem tissue, which may not represent the broader population, and the exclusion of cases with mosaicism and partial trisomy, potentially affecting generalizability.
- APOE genotype and Braak NFT staging data were not available for all groups, which may limit the understanding of genetic influences on pathology.
Conclusion:
The findings underscore the importance of monitoring tau pathology in individuals with Down syndrome as they age, given their heightened risk for Alzheimer's disease.
